Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced its Phase 3 clinical development program for Albuferon(TM) (albumin-interferon alpha 2b) in patients with chronic hepatitis C. "We believe that Albuferon could become the best-in-class immunomodulator in treatment regimens for chronic hepatitis C, and we are pleased to move this important program forward," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Advancing Albuferon to Phase 3 development is a major step toward the transformation of HGS into a development and commercialization company."
Via: First Call
Via: Forbes
Sponsor Media
Sponsor: 16x20.com
Great Wall Art For Everyone
Healthcare
Simple
- BlogPad (tm) NanoPublishing
Network of Blog Brands - Start Simple Naming
Publishers
- Brand Objects (tm) GUI
User Interface Development (UI/GUI) - Her Face (tm) Skincare
Tag Random Faces In NYC - NYC Film
Film Casting + Research
My Online Status
Network
Recent Comments
Sponsor Video
Sponsor: 16x20.com
Great Wall Art For Everyone
« Patients are increasingly getting vastly different medical opinions about the same problem, and are left wondering what's the best thing for their health. | Main | Introgen: ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers »
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341cce4453ef00d835360e1a53ef
Listed below are links to weblogs that reference Human Genome Sciences announced its Phase 3 clinical development for Albuferon(TM):
Verify your Comment
Previewing your Comment
This is only a preview. Your comment has not yet been posted.
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment
As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.
Having trouble reading this image? View an alternate.
Comments